sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: ALL (Acute Lymphatic Leukemia)

Trial: HOVON 117 ALL

1. Overview
Study details
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms

return to top


HO117 news

21 December 2018 - Overall closure of recruitment

27 January 2016 -Recruitment to the trial is suspended

1. Overview


A phase 2 study for older adults with Acute Lymphoblastic Leukaemia


on hold


University College London in association with HOVON

Validity no: NCT01616238

Study details

Type of study

Prospective Phase II study

Type of monitoring for this study

Site evaluation visits

Target number of patients


Current number of patients


Approved by


Study objectives

• Complete remission rate after 2 phases of induction
• EFS at 1 year
• Treatment related mortality
• Complete remission rate after 1 phase of induction
• Prognostic significance of molecularly determined minimal residual disease (MRD) at various time-points during therapy with respect to relapse occurrence.
• Overall Survival at 1 year
• Tolerability of treatment as determined by occurrence of key adverse effects
• Duration of in-patient hospitalisation
• Relationship between performance status/co-morbidity and treatment option chosen
• Quality of life aspects assessed at diagnosis/baseline at various time points.

2. Patient eligibility criteria

Inclusion criteria

• Age ≥ 60 with Acute Lymphoblastic Leukaemia (ALL) OR ≥ 55 with Acute Lymphoblastic Leukaemia (ALL) unsuitable for the UKALL14 or HOVON 100 trial
• Newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days may be given before study registration)
• Written informed consent

Exclusion criteria

• Known HIV infection
• Blast transformation of CML
• Mature B-cell leukaemia i.e. Burkitts disease t(8,14)(q24;q32) and variant c-myc translocations e.g. t(2;8)(p12;q24), t(8;22)(q24;q11)
• Women who are pregnant or lactating

3. Registration (& randomization) of patients


At UCL CTC +44 20 7679 9861

Registration criteria

The following information will be requested:

Following pre-treatment evaluations (as detailed in section 5.1), confirmation of eligibility and consent of a patient at a site, the registration form must be fully completed and then faxed to UCL CTC. The faxed registration form will be used to confirm patient eligibility at UCL CTC.
A study number and confirmation of treatment allocation will be assigned for the patient and details added to the form.

4. Participating parties

Principal Investigator(s)

Mw.Dr. A.W. Rijneveld (Erasmus MC)

Principal investigator

dr. A. Fielding (UCL)
mw.Dr. A.W. Rijneveld (HOVON)

Trial manager

E. Marwood - UKALL60+ Trial Coordinator (UCL)
I. Meulendijks (HDC)

Central data management


Other functions

Please contact monitors at

5. Participating sites

Included patients *
NL-Rotterdam-Erasmus MC

* Please note that if TOP is not used to register patients for a study, the number of patients shown is zero.

6. Instruction videos

7. Download documentation / forms

return to top